1. Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post‐transplant cyclophosphamide in AML in first complete remission.
- Author
-
Nagler, Arnon, Labopin, Myriam, Dholaria, Bhagirathbhai, Blaise, Didier, Bondarenko, Sergey, Vydra, Jan, Choi, Goda, Rovira, Montserrat, Reményi, Péter, Meijer, Ellen, Bulabois, Claude Eric, Diez‐Martin, J. L., Yakoub‐Agha, Ibrahim, Brissot, Eolia, Spyridonidis, Alexandros, Sanz, Jaime, Patel, Amit, Arat, Mutlu, Bazarbachi, Ali, and Bug, Gesine
- Subjects
CELL transplantation ,ACUTE myeloid leukemia ,CYCLOPHOSPHAMIDE ,MULTIVARIATE analysis ,OVERALL survival - Abstract
Summary: Pre‐transplant measurable residual disease (MRD) predicts relapse and outcome of allogeneic haematopoietic cell transplantation (allo‐HCT). The impact of MRD on the outcomes of post‐transplant cyclophosphamide (PTCy)‐based allo‐HCT from a matched unrelated donor (UD) is unknown. This study assessed the impact of MRD in acute myeloid leukaemia (AML) in the first complete remission (CR1). A total of 272 patients (MRD negative [MRD−], n = 165; MRD positive [MRD+], n = 107) with a median follow‐up of 19 (range: 16–24) months were studied. The incidence of grades II–IV and grades III–IV acute GVHD at day 180 was 25.2% and 25% (p = 0.99), and 10.6% and 6.8% (p = 0.29), respectively, and 2‐year chronic GVHD was 35% and 30.4% (p = 0.96) in MRD+ and MRD− cohorts, respectively. In multivariate analysis, MRD+ status was associated with a higher incidence of relapse (RI) (hazard ratio [HR] = 2.56, 95% CI: 1.39–4.72), lower leukaemia‐free survival (LFS) (HR = 2.04, 95% CI: 1.23–3.39), overall survival (OS) (HR = 1.83, 95% CI: 1.04–3.25) and GVHD‐free, relapse‐free survival (GRFS) (HR = 1.69, 95% CI: 1.10–2.58). MRD status did not have a significant impact on non‐relapse mortality (NRM), or acute or chronic GVHD risk. Among patients with AML undergoing UD allo‐HCT with PTCy, pre‐transplant MRD+ status predicted a higher relapse rate, lower LFS, OS and GRFS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF